Pfizer (NYSE:PFE) Releases FY 2026 Earnings Guidance

Pfizer (NYSE:PFE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.000 for the period, compared to the consensus earnings per share estimate of 2.970. The company issued revenue guidance of $60.5 billion-$62.5 billion, compared to the consensus revenue estimate of $61.7 billion.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.51 during mid-day trading on Tuesday, hitting $25.54. The company had a trading volume of 27,800,599 shares, compared to its average volume of 42,138,285. Pfizer has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a market cap of $145.55 billion, a price-to-earnings ratio of 19.49 and a beta of 0.34. The firm’s 50 day simple moving average is $25.03 and its two-hundred day simple moving average is $26.16. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $0.78 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Quarterly results exceeded expectations: Pfizer reported adjusted earnings of $0.77 per share, above the $0.68 consensus estimate, while revenue reached $15.03 billion versus expectations of $14.40 billion. Revenue increased 2.6% year over year. Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
• Positive Sentiment: Non-COVID products are supporting growth: Strong demand for Eliquis, along with oncology and other launched or acquired products, helped offset weaker COVID-19 vaccine and treatment sales. This suggests Pfizer’s effort to diversify beyond pandemic-related revenue is gaining traction. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Full-year revenue outlook improved: Pfizer raised its 2026 revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, increasing the midpoint by $500 million. The company reaffirmed adjusted EPS guidance of $2.80-$3.00. Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
• Neutral Sentiment: Guidance remains broadly in line with forecasts: The EPS outlook is near the $2.97 analyst consensus, and the revenue range encompasses the approximately $61.7 billion consensus estimate. Pfizer said the Innovent Biologics transaction will reduce adjusted EPS by roughly $0.10.
• Negative Sentiment: Legacy headwinds remain: Pfizer swung to a quarterly loss on a reported basis, and second-quarter EPS was slightly below the year-ago $0.78. Continued declines in COVID-19 products and the relatively modest guidance increase limited the market’s enthusiasm. Pfizer Post Loss on Higher Revenue

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Morgan Stanley grew its stake in shares of Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after purchasing an additional 7,489,189 shares during the last quarter. Amundi boosted its position in Pfizer by 13.4% in the fourth quarter. Amundi now owns 47,063,380 shares of the biopharmaceutical company’s stock valued at $1,171,879,000 after buying an additional 5,572,451 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Pfizer by 120.9% during the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new position in Pfizer during the fourth quarter worth $105,709,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.